Pharmacokinetics and Tolerability of Naftopidil after a Single Oral Administration in Healthy Korean Volunteers

건강한 한국인 자원자에서 나프토피딜(Naftopidil) 단회 경구투여에 의한 약동학적 특성 및 내약성에 관한 연구

  • Cha, Yu-Jung (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Kim, Jung-Won (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Jeon, Hye-Won (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Shin, Kwang-Hee (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Lee, Seung-Hwan (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Jang, In-Jin (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Shin, Sang-Goo (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Yu, Kyung-Sang (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital)
  • 차유정 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 김정원 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 전혜원 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 신광희 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 이승환 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 장인진 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 신상구 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 유경상 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과)
  • Received : 2010.12.24
  • Accepted : 2010.12.30
  • Published : 2010.12.30

Abstract

Background: Naftopidil is a selective ${\alpha}_1$ adrenergic receptor antagonist which is used for the treatment of dysuria caused by benign prostatic hyperplasia. We investigated the pharmacokinetic characteristics and tolerability of naftopidil after a single oral dose in healthy Korean male volunteers. Methods: Sixteen subjects were allocated into two groups (8 for naftopidil 50 mg and 75 mg, 8 for naftopidil 25 mg and 100 mg). Serial blood samples for pharmacokinetics were collected up to 24 hours after drug administration. Naftopidil plasma concentrations were determined by HPLC. The pharmacokinetic parameters were calculated by noncompartmental methods. Tolerability assessments including vital signs, 12-lead ECG, clinical laboratory parameters, and adverse events were conducted. Results: The median time of maximum observed plasma concentration ($T_{max}$) was 0.5 h in all dose groups. The maximum plasma concentration ($C_{max}$) of 25, 50, 75 and 100 mg dose group were $44.0\;{\mu}g/L$, $88.9\;{\mu}g/L$, $114.3\;{\mu}g/L$, and $179.5\;{\mu}g/L$, respectively. The area under the concentration-time curve to the last measured concentration over the limit of quantitation ($AUC_{last}$) of respective dose groups were $71.1\;{\mu}g{\ast}h/L$, $178.7\;{\mu}g{\ast}h/L$, $298.3\;{\mu}g{\ast}h/L$, and $342.6\;{\mu}g{\ast}h/L$, respectively. Conclusion: The results of this study indicate that the systemic exposure of naftopidil expressed $AUC_{last}$ and $C_{max}$ was increased dose proportionally, and all doses. Up to 100 mg were well tolerated without serious adverse events in healthy Korean male volunteers.

Keywords

References

  1. Garimella PS, Fink HA, Roderick MacDonald R, Wilt. TJ. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.(Review) The Cochrane Library, 2009;4:1-2.
  2. Sant GR. Pathophysiologic Principles of Urology: Blackwell Scientific Publications, Boston, 1994;123-154.
  3. Hyoung-Keun Park, Hong-Zoo Park, Sung-Yong Cho, Jung-Bum Bae, Seong-Jin Jeong, Sung-Kyu Hong, Cheol-Yong Yoon, Seok-Soo Byun, Sang-Eun Lee, Ki-Woong Kim. The Prevalence of Benign Prostatic Hyperplasia in Elderly Men in Korea: A Community-Based Study. Kor J Urology, 2009;50(9):843-847.(Korean) https://doi.org/10.4111/kju.2009.50.9.843
  4. Flivas${\circledR}$(Naftopidil), Investigator's Brochure, Dong-A Pharmaceutical Company
  5. Ethnic factors in the acceptability of foreign clinical data E5, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Current Step 4 version, 1998.
  6. 가교자료평가 가이드라인, 식품의약품안전청, 2008.
  7. Katzung BG. Basic and Clinical Pharmacology: $7^{th}$. ed. Appleton & Lange, Stamford, CT, 1998;119-129.
  8. Himmel HM. Naftopidil, A Novel Antihypertensive Drug. Cardiovascular Drug Reviews 1994;12(1):32-41. https://doi.org/10.1111/j.1527-3466.1994.tb00282.x
  9. Nakashima M, Uematsu T, Kanamura M. Phase I clinical study of naftopidil (KT-611), a new $\alpha$-adrenoceptor blocker. J Clin Ther Med. 1992;8(3):11-29.
  10. Hobbs DC, Twomey TM, Palmer RF. Pharmacokinetics of prazosin in man. Clin Pharmacol. 1978;18(8):402-406. https://doi.org/10.1002/j.1552-4604.1978.tb02456.x